Anti-TCR Vb6/Vb10/IL-2 Antibody Fusion Protein STAR0602 clinical trials
Also written STAR0602.
How each study uses Anti-TCR Vb6/Vb10/IL-2 Antibody Fusion Protein STAR0602 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Keep track of what changes. Save the Anti-TCR Vb6/Vb10/IL-2 Antibody Fusion Protein STAR0602 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesApprovals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- STAR0602
- 3
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Marengo Therapeutics, Inc. (2) · National Cancer Institute (NCI) (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Anti-TCR Vb6/Vb10/IL-2 Antibody Fusion Protein STAR0602.
- Jan 2027A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid TumorsPhase 1/2 · Marengo Therapeutics, Inc.
- Sep 2027A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsPhase 1/2 · Marengo Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses Anti-TCR Vb6/Vb10/IL-2 Antibody Fusion Protein STAR0602 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic CarcinomaNot yet recruitingPhase 1/2National Cancer Institute (NCI)NCT07902921Written as STAR0602
- A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsRecruitingPhase 1/2Marengo Therapeutics, Inc.NCT05592626Written as STAR0602
- A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid TumorsRecruitingPhase 1/2Marengo Therapeutics, Inc.NCT06827613Written as STAR0602